EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Revenue

EQL Pharma AB had revenue of 92.22M SEK in the quarter ending December 31, 2024, with 31.35% growth. This brings the company's revenue in the last twelve months to 338.39M, up 37.35% year-over-year. In the fiscal year ending March 31, 2024, EQL Pharma AB had annual revenue of 264.17M with 1.64% growth.

• Revenue (ttm): 338.39M
• Revenue Growth: +37.35%
• P/S Ratio: 7.20
• Revenue / Employee: 12.09M
• Employees: 21
• Market Cap: 2.44B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2024	264.17M	4.26M	1.64%
Mar 31, 2023	259.91M	-149.84M	-36.57%
Mar 31, 2022	409.75M	230.61M	128.73%
Mar 31, 2021	179.14M	107.11M	148.70%
Mar 31, 2020	72.03M	22.28M	44.77%